Geovax Labs Stock Keeps Soaring, Grabs Most Retail Attention As Mpox Concerns Grow

Geovax Labs (GOVX) is currently the hottest stock on Stocktwits, with shares surging over 56% in pre-market trading on Monday. Notably, the rally follows a near 111% rise in the stock price on Friday.

The company’s new retail followers on Stocktwits jumped by 9% and message volume exploded by over 8,300% in the past week.

This meteoric rise is largely attributed to the increased focus on mpox following the World Health Organization's declaration of a global health emergency. The European Centre for Disease Prevention and Control (ECDC) has also issued a new risk assessment, further fueling concerns about the disease.

Geovax has positioned itself as a potential key player in the fight against mpox. The company previously published research suggesting its vaccines could help prevent the disease and expanded its commercial license to include mpox and smallpox in December 2023.

Brokerage Roth MKM reportedly believes Geovax's GEO-MVA vaccine could be the first product to market for mpox.

In contrast, Siga Technologies (SIGA), an earlier frontrunner in the mpox treatment space,saw its stock decline over 2% in Monday’s premarket session. This follows disappointing top-line results from a trial testing its TPOXX drug for mpox. While the drug showed some clinical benefits, it failed to meet its primary endpoint.

Interestingly, despite the setback, retail investor sentiment for SIGA on Stocktwits has surprisingly flipped to ‘extremely bullish’ territory (93/100), suggesting hopes for a turnaround.

While both companies are in the spotlight due to the mpox outbreak, Geovax has clearly captured more retail investor attention for now.

https://stocktwits.com/RWROCKPORT/message/583340518 

Year-to-date, GOVX has gained over 27%, while SIGA is up 80%.